Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
The fair value price target for Curis has been reset from US$280.00 to US$42.67, which represents a very large downward adjustment in the modeled target level. Analysts link this shift to updated assumptions around emavusertib and the TakeAim chronic lymphocytic leukemia study, where price targets now reflect explicit probabilities of success, peak sales estimates and timing. As you read on, you will see how this evolving narrative around Curis might influence the way you track the stock from here.
Stay updated as the Fair Value for Curis shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Curis.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
H.C. Wainwright recently lifted its Curis price target from US$17 to US$43 after adding a valuation for emavusertib in chronic lymphocytic leukemia. This signals higher conviction in the program's potential contribution to the overall model.
-
The firm now explicitly includes a 10% probability of success for emavusertib against projected peak sales of US$500m. This gives investors a clearer view of how the TakeAim study feeds into long term revenue scenarios and valuation assumptions.
-
By assigning a specific launch year in its research, H.C. Wainwright provides a more structured timeline for Curis related cash flow expectations. Some investors may find this helpful when thinking about portfolio holding periods and risk budgeting.
🐻 Bearish Takeaways
-
The 10% probability of success that H.C. Wainwright applies to emavusertib underscores the high execution risk that still surrounds the TakeAim chronic lymphocytic leukemia program, especially at this stage of development.
-
H.C. Wainwright's framework hinges on future peak sales and a specific launch year. Any delay in the clinical path or changes to study outcomes could have a meaningful effect on Curis valuation models.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 4 risks for Curis. See which could impact your investment.
How This Changes the Fair Value For Curis
-
Fair Value has moved from US$280.00 to US$42.67, representing a significant downward reset in the modeled target level.
-
Revenue Growth remains at about 92.96%, with no material change in the long-term top line assumption.
-
Profit Margin has shifted from 17.20% to 17.93%, reflecting slightly higher modeled long-run profitability.
-
Future P/E has moved from 79.41x to 11.63x, indicating a much lower earnings multiple in the current framework.
-
The Discount Rate has adjusted from 7.37% to 7.45%, which points to a modestly higher required return in the model.
Never Miss an Update: Follow The Narrative
Narratives connect Curis' clinical story and business decisions to a forward-looking earnings path and fair value framework. They refresh automatically when new clinical data, funding moves, or regulatory updates come through.
Head over to the Simply Wall St Community and follow the Narrative on Curis to stay up to date on:
-
How progress in the TakeAim CLL and other emavusertib studies across hematologic cancers could shape future market opportunities and revenue potential.
-
What externally funded trials and cost controls might mean for Curis' cash burn, runway, and eventual path toward profitability.
-
Key risks such as reliance on a single lead asset, competition from other cancer therapies, funding needs, and a challenging oncology regulatory setting.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CRIS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
